Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective

References

• EdwardsBKBrownMLWingoPAAnnual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatmentJ Natl Cancer Inst200597191407142716204691
   PubMed Web of Science ®Google Scholar
• Instituto Nacional do CancerEstimativa 2010: Incidencia de Cancer no Brasil [Cancer Incidence in Brazil: 2010 Estimates]Rio de JaneiroInstituto Nacional do Cancer2009 Portuguese
   Google Scholar
• LeeBLLiedkePEBarriosCHSimonSDFinkelsteinDMGossPEBreast cancer in Brazil: present status and future goalsLancet Oncol2012133e95e10222381937
   PubMed Web of Science ®Google Scholar
• Fundacao Oncocentro de Sao PauloDados de cancer: registro hospitalar de cancer, 2001–2008 [Cancer data: hospital cancer registries, 2001–2008]2008 Available from: http://www.fosp.saude.sp.gov.br/html/fr_dados.htmlAccessed June 12, 2012 Portuguese
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist200914432036819346299
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• MauriDPolyzosNPSalantiGPavlidisNIoannidisJPMultiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancerJ Natl Cancer Inst2008100241780179119066278
   PubMedGoogle Scholar
• HarrisCAWardRLDobbinsTADrewAKPearsonSThe efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysisAnn Oncol20112261308131721119031
   PubMed Web of Science ®Google Scholar
• CardosoFFallowfeldLCostaACastiglioneMSenkusELocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201122Suppl 6vi25vi3021908499
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology72004 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed June 11, 2012
   Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• FabiAMetroGFerrettiGDo HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesBreast200817549950518450443
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• Ministerio da Saude do BrasilTrastuzumabe para tratamento do cancer de mama inicial [Trastuzumab for the treatment of initial stage breast cancer]52012 Available from: http://portal.saude.gov.br/portal/arquivos/pdf/Relatorio_Trastuzumabe_ca_inicial.pdfAccessed June 18, 2012 Portuguese
   Google Scholar
• Ministerio da Saude do BrasilTrastuzumabe para tratamento do cancer de mama avancado [Trastuzumab for the treatment of advanced stage breast cancer]52012 Available from: http://portal.saude.gov.br/portal/arquivos/pdf/Relatorio_Trastuzumabe_ca_avancado.pdfAccessed June 18, 2012 Portuguese
   Google Scholar
• Ministerio da Saude do BrasilEstudos de avaliacao economica de technologias em saude [Economic evaluation studies of technologies in health]2009 Available from: http://www.ispor.org/PEguidelines/source/Economic-Evaluation-Guidelines-in-Brazil-Final-Version-2009.pdfAccessed March 13, 2012 Portuguese
   Google Scholar
• DeleaTETappendenPSofryginOCost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumabEur J Health Econ201213558960321701940
   PubMed Web of Science ®Google Scholar
• DrummondMBarbieriMCookJTransferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportValue Health200912440941819900249
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat2008112353354318188694
   PubMed Web of Science ®Google Scholar
• von MinckwitzGdu BoisASchmidtMTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 studyJ Clin Oncol200927121999200619289619
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMOlivaCNewstatBImwalleBGeyerCELapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trialOncologist201015992493420736298
   PubMed Web of Science ®Google Scholar
• von MinckwitzGSchwedlerKSchmidtMTrastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancerEur J Cancer201147152273228121741829
   PubMed Web of Science ®Google Scholar
• ZhouXCellaDCameronDLapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessmentBreast Cancer Res Treat2009117357758919153829
   PubMed Web of Science ®Google Scholar
• LloydANafeesBNarewskaJDewildeSWatkinsJHealth state utilities for metastatic breast cancerBr J Cancer200695668369016967055
   PubMed Web of Science ®Google Scholar
• CarrollKJOn the use and utility of the Weibull model in the analysis of survival dataControl Clin Trials200324668270114662274
   PubMedGoogle Scholar
• Ministerio da Saude do Brasil[Health Price Database – version 2.0.1] Available from: http://bps.saude.gov.br/login.cfm112011Accessed March 13, 2012 Portuguese
   Google Scholar
• Ministerio da Saude[SIGTAP – Management System for Medical Procedures]112008 Available from: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jspAccessed March 13, 2012 Portuguese
   Google Scholar
• National Institute for Health and Clinical ExcellenceGuide to the methods of technology appraisal12009 Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jspAccessed March 13, 2012
   Google Scholar
• LaupacisAFeenyDDetskyASTugwellPXHow attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsCMAJ199214644734811306034
   PubMed Web of Science ®Google Scholar
• LeQAHayJWCost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancerCancer2009115348949819117341
   PubMed Web of Science ®Google Scholar
• Matter-WalstraKWDedesKJSchwenkglenksMBrauchliPSzucsTDPestalozziBCTrastuzumab beyond progression: a cost-utility analysisAnn Oncol201021112161216820444849
   PubMed Web of Science ®Google Scholar
• ChanALLeungHWLuCLLinSJCost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic reviewAnn Pharmacother200943229630319193576
   PubMed Web of Science ®Google Scholar
• HurvitzSAKakkarARole of lapatinib alone or in combination in the treatment of HER2-positive breast cancerBreast Cancer (London)2012413551
   PubMedGoogle Scholar
• JohnstonSPippenJJrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• CassidyJTwelvesCVan CutsemEFirst-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorinAnn Oncol200213456657512056707
   PubMed Web of Science ®Google Scholar
• LinNUBellonJRWinerEPCNS metastases in breast cancerJ Clin Oncol200422173608361715337811
   PubMed Web of Science ®Google Scholar
• ClaytonAJDansonSJollySIncidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBr J Cancer200491463964315266327
   PubMed Web of Science ®Google Scholar